about
Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based RegimensA phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial)
P50
description
researcher
@en
name
Shin Young Hyun
@en
type
label
Shin Young Hyun
@en
prefLabel
Shin Young Hyun
@en
P31
P496
0000-0002-8137-8675